Etoposide and adriamycin containing combination chemotherapy (HOPE-Bleo) for relapsed Hodgkin's disease. by Perren, T. J. et al.
Br.J.Cancer(1990),61,919923 t~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Macmillan Press Ltd., 1990~~~~~~~~~~~~~~~~~~--
Etoposide and adriamycin containing combination chemotherapy
(HOPE-Bleo) for relapsed Hodgkin's disease
T.J. Perren, P.J. Selby, S. Milan', M. Meldrum & T.J. McElwain
Section ofMedicine and 'Department ofComputing, Institute ofCancer Research, Royal Marsden Hospital, Down Road, Sutton,
Surrey SM2 5PT, UK.
Summary Forty-four patients with relapsed or resistant Hodgkin's disease were treated with adriamycin
40 mg m 2 i.v. on day 1, vincristine 1.4 mg m -i.v. on days 1 and 8, prednisolone 40 mg m 2 orally daily for 8
days, etoposide 200 mgm-2 orally daily for 4 days according to the nadir white cell count, and bleomycin
10 mgm2 i.v. days I and 8 (HOPE-Bleo). Median age was 27 (range 12-71). When stage was considered
according to all sites currently or previously involved by Hodgkin's disease (cumulative stage) 26 patients
(59%) had stage IV, 13 (29%) stage III and five (11%) stage II disease; 33 (75%) had B symptoms. All
patients had received previous chemotherapy and 18 (41%) had received two or more regimens. Twenty-six
patients (59%) achieved CR and 10 (23%) PR; the median duration of CR was 22 months and median
survival for all patients was 48 months. Eight patients remain in continuous CR; none of these had received
extensive previous chemotherapy. Among the 19 patients who had relapsed from CR achieved by a single
previous chemotherapy regimen, six (32%) achieved long CR on HOPE-Bleo. The regimen was generally well
tolerated but the principal toxicity was myelosuppression. There were two toxic deaths, one due to neutropenic
sepsis and the other due to acute peritonitis. The HOPE-Bleo regimen is an effective treatment for relapsed or
resistant Hodgkin's disease, with a low probability of carcinogenesis and infertility. These factors suggest that
HOPE-Bleo deserves further evaluation as primary treatment for Hodgkin's disease and very careful selection
of relapsed patients for high dose salvage chemotherapy with bone marrow transplants must be exercised.
Combination chemotherapy for Hodgkin's disease based
upon the MOPP regimen (mustine, vincristine, procarbazine
and prednisolone) or its variants will produce complete re-
mission in 60-80% of patients with advanced disease but
20-40% of these will relapse (reviewed by Selby et al., 1987).
The MOPP regimen results in substantial acute toxicity such
as nausea, vomiting, hair loss and neuropathy, and also in
long term morbidity such as second malignancies and sterility
in men (DeVita et al., 1980; Selby et al., 1987; Colman &
Selby, 1987; Sutcliffe, 1987). Variations of the MOPP regi-
men incorporating alternative alkylating agents or alternative
vinca alkaloids substantially reduce the acute toxicity but do
not appear to increase the proportion of patients achieving
complete remission or who are cured, neither do they remove
the risk of leukaemia and infertility (Selby et al., 1990).
Despite the success of MOPP and its variants, their limita-
tions have led to a search for second line or alternative
combination chemotherapy regimens for Hodgkin's disease.
Single agents with activity in this disease include adriamycin,
bleomycin, dacarbazine and etoposide. The first major devel-
opment of an effective alternative combination was the
ABVD regimen from the Milan Cancer Institute (Bonadonna
et al., 1985); in a recent survey of the literature the ABVD
regimen when used as second line chemotherapy for patients
with disease resistant to MOPP, or similar chemotherapy
resulted in complete a remission for 75 of 232 patients (32%)
(Canellos et al., 1987). The follow-up available from this
study suggests that about one third of the patients achieving
CR will remain disease-free for long periods (Santoro et al.,
1982). Although the ABVD regimen is not strongly assoc-
iated with long-term infertility in males or secondary acute
leukaemia, patients who receive this treatment do experience
severe acute toxicity with nausea and vomiting and hair loss.
The single agent activity of etoposide ini Hodgkin's disease
together with its lack of acute toxicity (Taylor et al., 1982)
has led us to develop combinations with this drug. We have
used a regimen known as HOPE-Bleo for the treatment of
relapsed HD in which adriamycin, vincristine, bleomycin and
prednisolone were combined with etoposide. The majority of
surviving patients treated with this regimen have been follow-
ed up beyond 3 years, which leads us to now report the
results.
Patients, materials and methods
Treatment regimen
The regimen is shown in Table I. Treatment was delivered in
outpatients, where patients were required to attend on day 1
and day 8. Nadir blood counts (days 10-14) were routinely
taken during the first three cycles in order to allow biotitra-
tion of the oral dose of etoposide. Treatment was repeated
after 3 weeks or when the white cell count exceeded
3 x I09 1-' and platelet count exceeded 100 x 109 1 ', a max-
imum of eight courses of treatment were given.
Patients
Forty-four patients with relapsed or resistant Hodgkin's
disease were entered into the study. The study was approved
by the institutional ethical review committee and patients
gave verbal, witnessed informed consent.
The median age of the patients was 27 years (range 12-71
years), 28 patients were aged 21-40 and only three were over
the age of 50; 30 patients were male and 14 female. The
histological subtype (Lukes & Butler, 1966) was nodular
sclerosis in 31, mixed cellularity in 11, lymphocyte predom-
inance in one and lymphocyte depletion in one patient. Clini-
cal stage at presentation is shown in Table II together with
an indication of the cumulative stage, a term we have used to
indicate the sum of all sites currently or previously involved
by Hodgkin's disease. Cumulative stage is designed to give an
indication of the extent of disease at the time of HOPE-Bleo
treatment, we would however emphasize that this is not a
conventional usage of the Ann Arbor Staging System (Car-
bone et al., 1971).
The median follow-up for surviving patients is 52 months
with a range of 28-74 months. The distribution of patients
according to their previous chemotherapy regimens and pre-
vious remission durations are shown in Tables III and IV.
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Table I HOPE-Bleo regimen
Adriamycin 40mg m2 i.v. day 1
Vincristine 1.4mg m2 i.v. days 1 and 8 (max 2mg)
Prednisolone 40mgm-2 p.o. daily for 8 days (max 60mg)
Etoposidea 200 mgm-2 p.o. daily for 4 days according to
nadir FBC
Bleomycin 10mgm-2 i.v. day 1 and 8
alf the nadir (days 10-14) WBC<1.0 x 10-', decrease
etoposide to 3 days. If nadir WBC> 1.5 x I091-', increase etoposide
to 5 days. Etoposide also reduced to 3 days in heavily pre-treated
patients. Repeat every 21 days.
Table II Stage
Cumulative stage
at HOPE-Bleo
At presentation treatmenta
IA 3 0
IIA 7 2
IIB 6 3
IIIA 8 4
IIIB 8 9
IVA 3 5
IVB 9 21
Sites of extra nodal disease at HOPE-Bleo treatment: lung 16
patients, liver 16 patients, marrow 7 patients, bone 6 patients.
aCumulative stage represents the stage according to the Ann Arbor
system resulting from considering all sites involved by Hodgkin's
disease for a given patient during previous presentations and relapse.
Staging investigations
Patients were staged by clinical assessment, full blood count,
ESR, liver function tests, chest X-ray, lymphogram and bone
marrow aspirate and trephine in all cases, with liver ultra-
sound scan, isotope liver scan or CT scan of the chest and
abdomen when indicated. Complete remission was docu-
mented by repeating all previously abnormal investigations at
the end of treatment.
Statistics
Remission rates were compared using non-parametric tests
including x2, Fisher's exact probability and Mann-Whitney
U tests. Curves for survival and duration of complete remis-
sion were calculated according to the method of Kaplan and
Meier (1958). Survival and remission duration were both
measured from the date of the first course of treatment.
Results
Forty-four patients received the HOPE-Bleo regimen.
Twenty-four received six courses and only three patients
received more than six courses.
Table V shows the response of patients to HOPE-Bleo.
The complete remission rate for all patients was 59%, with
23% partial remissions and 14% non responders. There were
two early deaths (day 13 and day 17). In Tables III and IV
the response rate is shown according to the number of
previous chemotherapy regimens. As expected, the complete
remission rate to HOPE-Bleo fell with increasing numbers of
previous chemotherapy regimens from 73% for patients who
have received only one previous regimen to 0% among the
four patients who had received four or more treatments
(P = 0.003). Patients who had not previously received adria-
mycin were more likely to enter complete remission (66%
against 25%, P = 0.04) and there was a trend favouring
patients who had not previously received etoposide but this
did not achieve statistical significance (P = 0.14). The prob-
ability of CR on HOPE-Bleo was examined with respect to
the responses achieved with previous chemotherapy regimens
(Table IV). If the durations of PR and NR are scored as zero
then the association between chance of CR on HOPE-Bleo
and the duration of previous remissions was marginally sig-
nificant (P = 0.053). We could not show that the duration of
the longest previous complete remission to any treatment
influenced outcome in this study although the numbers are
small.
Five patients who responded to HOPE-Bleo proceeded to
high dose consolidation chemotherapy with autologous bone
marrow grafting (the high dose melphalan and MBE regi-
Table IV Remission rate to HOPE-Bleo related to response to
previous chemotherapy regimens
No. (%) achieving
CR with
Outcome on previous regimen Patients HOPE-Bleo
Response to regimen before HOPE-Bleo
No response 5 1 (20%)
Partial remission 12 6 (50%)
Complete remission
Any CR 27 19 (70%)
CR 0-2 years 16 11 (69%)
CR 2-4 years 6 4 (66%)
CR >4 years 5 4 (80%)
Longest previous CR on any chemotherapy
None 11 6 (55%)
0-2 years 16 8 (50%)
2-4 years 8 5 (63%)
>4 years 9 7 (78%)
Table V Response rate
Patients 95% CI
CR 26 (59%) 45-74%
PR 10 (23%) 10-35%
NR 6 (14%) 4-24%
ED 2 (5%) 0-11%
ED: day 13 (sepsis), day 17 (acute abdomen). CR, complete
remission; PR, partial remission; NR, no response; ED, death within
30 days of treatment; CI, confidence interval. Total 44 patients.
Table III Response to HOPE-Bleo related to details of previous chemotherapy
No. (%) achieving
Patients CR with HOPE-Bleo P
All 44 26 (59%)
Number of previous 1 26 19 (73%) 0.003
chemotherapy regimens 2 11 6 (55%)
3 3 1 (33%)
>4 4 0
Never in CR 11 6 (55%) n.s.
Previous CR 33 20 (61%)
Previous adriamycin 8 2 (25%) 0.04
No previous adriamycin 36 24 (66%)
Previous etoposide 19 9 (47%) 0.14
No previous etoposide 25 17 (68%)HOPE-Bleo FOR RELAPSED HODGKIN'S DISEASE 921
Table VI Long-term CR after HOPE-Bleo
Duration
of CR on Further Cumulative Previous
HOPE-Bleo treatment Age Stage at chemotherapy
No. (months) in CR (years) HOPE-Bleoa (and outcome in months)
1 37 + - 25 4A ChlVPP (CR, 93)
2 41 + RT 56 3A ChlVPP (CR, 49)
3 38 + RT 44 3B ChIVPP (PR) OPEC (CR, 47)
4 74 + 23 4B OPEC/ChIVPP (CR, 16)
5 59 + 34 3B OPEC/ChIVPP (CR, 16)
6 35 + RT 14 3A ChlVPP (CR, 15)
7 53 + 12 3B ChlVPP (PR)
8 28 + RT 42 2B ChIVPP (CR, 6)
aSee Table II.
mens: see Zulian et al., 1989; Russell et al., 1989). These are
censored from the analysis of relapse at the time of their high
dose treatment but remain in the group for survival analysis.
One of these died during the procedure and one died 1 year
later of chronic lung toxicity. Two are alive and in complete
remission (12 and 33 months after ABMT) and one is alive
but has relapsed (8 months after ABMT).
Eight patients achieved continuous complete remission
with HOPE-Bleo and have not required further
chemotherapy. Their details are given in Table VI. Since the
majority of relapses in Hodgkin's disease would be
anticipated within the first 3 years these patients may well
have been cured by this regimen. Four of the patients
received involved field radiotherapy following HOPE-Bleo
and the contribution of radiotherapy to these possible cures
is unclear. However, the widespread extent of disease at the
time of HOPE-Bleo chemotherapy makes a cure by
radiotherapy alone seem unlikely. The outstanding and con-
sistent feature is that none of these patients had received very
extensive previous chemotherapy. Seven had only received
one regimen and the other patient had received Ch1VPP
followed by OPEC (vincristine, prednisolone, etoposide and
chlorambucil) in a single sequence of treatments without a
gap because there was uncertainty about the completeness of
the remission on ChlVPP alone. Only one patient whose
disease clearly did not enter complete remission on ChlVPP
(patient 7 in Table VI) appears to have been cured by the
HOPE-Bleo regimen. No patients who had received previous
adriamycin chemotherapy achieved lasting complete remis-
sion.
Among the 11 patients who had never previously entered
complete remission, six entered complete remission on
HOPE-Bleo (55%) but five of these relapsed after only 5-8
months ofcomplete remission, the remaining patient (no. 7 in
Table VI) has obtained a durable CR.
Curves for survival and durability of complete remission
are shown in Figures I and 2 for all patients.
Toxicity
Table VII summarises the toxicity from HOPE-Bleo chemo-
therapy according to WHO grades (WHO, 1979); for each
patient the maximum toxicity experienced at any time during
treatment is shown. The principal toxicity was myelosuppres-
sion and 23% of patients suffered grade 3-4 leucopenia at
some point during treatment. There were two toxic deaths.
One due to neutropenic sepsis at day 13 and the other due to
acute peritonitis without a microbiological diagnosis or
apparent perforated viscus occurring at day 17. Although the
explanation for the acute abdomen remains unclear we have
regarded it as a toxic complication of the treatment.
The number of patients receiving each course of chemo-
therapy, together with course by course details of treatment
delays and the number of drugs requiring dose reduction, is
shown in Table VIII. Delays in chemotherapy administration
were necessary in about 20% of patients. Dose reduction of
etoposide was necessary in 5-8 patients during each of the
first six courses according to nadir blood counts.
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Figure 1 Survival for all patients treated with HOPE-Bleo.
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Figure 2 Freedom from relapse for 26 patients achieving com-
plete remission on HOPE-Bleo.
Table VII Toxicity
Percentage ofpatientsa in each WHO grade
None 1 2 3 4
Anaemia 57 20 14 7 2
Leucopenia 36 16 25 7 16
Thrombocytopenia 91 0 5 0 5
Nausea and vomiting 41 30 23 7 0
Alopecia 30 5 16 48 2
Neuropathy 55 23 18 5 0
Infection 59 7 9 20 2
Diarrhoea 93 2 2 2 0
Stomatitis 84 7 7 2 0
Other recorded 95 0 5 2 0
aData complete on all 44 patients. For each toxicity the worst
toxicity experienced by each patient at any time during treatment is
shown.922 T.J. PERREN et al.
Table VIII Drug reduction and delay by course of treatment
Number of course
1 2 3 4 5 6 7 8
Number of patients 44 41 39 33 30 24 3 2
Number of patients with reduction of one or
more drugs
Any reduction 9 13 15 14 13 8 1 1
1 drug reduced 5 8 8 7 6 5 1 1
2 drugs reduced 2 3 5 4 4 1 0 0
3 drugs reduced 1 1 1 2 2 1 0 0
4 drugs reduced 1 1 1 1 1 1 0 0
Number of patients with treatment delay
Any delay - 9 8 9 9 6 1 1
1 week delay - 6 7 9 8 5 1 0
>1 week delay - 3 1 0 1 1 0 1
Discussion
The HOPE-Bleo regimen is an effective treatment for re-
lapsed or resistant Hodgkin's disease. It is readily delivered
in the outpatient clinic provided that careful attention is
given to haematological monitoring, particularly at the nadir
following each course of treatment as myelosuppression was
severe in a small proportion of these pretreated patients.
Acute subjective toxicity was moderate with alopecia and
mild gastrointestinal toxicity occuring in the majority of
patients.
Comparison with existing reports is always difficult be-
cause of the differing patient populations studied. However,
the majority of patients in this series had extranodal disease
and B symptoms, the CR rate achieved suggests that the
activity of HOPE-Bleo is probably as great as that of the
ABVD regimen with a similar number of prolonged remis-
sions (see Canellos et al., 1987 for review). As expected the
complete remission rate and the probability of a long term
remission were both related to the previous sensitivity of the
patient's disease to treatment and to the amount of previous
chemotherapy received, as judged by the number of regimens
and the previous use of drugs other than those included in
the basic MOPP regimen or its variants. These data and the
available literature do not, however, allow us to conclude
with certainty that second line treatment with adriamycin
containing combinations is superior to retreatment with
MOPP-based regimens for patients relapsing from a long
MOPP-induced CR (Fisher et al., 1979; Canellos et al.,
1987).
These data with long follow-up in a moderate number of
relapsed patients suggest that HOPE-Bleo might prove to be
as effective as the ABVD regimen as a primary treatment for
Hodgkin's disease, and in view of its ease of administration,
modest acute toxicity and low probabilty ofcarcinogenesis or
infertility we feel that this possibility should be further ex-
plored. The results of studies where MOPP or related
regimens are alternated with etoposide containing regimens
similar to HOPE-Bleo are awaited with interest and
preliminary results are encouraging (M. Cullen and B. Han-
cock, personal communications).
Some lessons can be inferred from the results of this study
for the management of Hodgkin's disease in relapse. Overall
only a small proportion of patients who relapse following
chemotherapy are likely to be cured by a subsequent com-
bination chemotherapy regimen. Nevertheless, eight patients
in this study, who had had only one or two previous treat-
ment regimens, have achieved long disease-free intervals and
are probably cured. The most powerful factors predicting for
a good prognosis are, in combination, a small amount of
previous chemotherapy and a long previous remission, and
among 19 patients, in this study, who had relapsed from
complete remission achieved by a single previous chemo-
therapy regimen, six (32%) achieved long-term complete re-
mission.
These results suggest caution in the use of intensive and
dangerous consolidation treatment such as high dose chemo-
therapy with autologous bone marrow transplantation (Zul-
ian et al., 1989; Russell et al., 1989; Canellos et al., 1987).
Patients who enter CR on initial chemotherapy, relapse and
then re-enter CR on second line chemotherapy have about a
30% chance of achieving long remission or cure and for such
patients a policy of observation, perhaps with marrow cryo-
preservation, may be advisable. If, however, a patient fails to
enter CR or has relapsed from CR more than once, and has
B symptoms and extra nodal disease then the prognosis is
very poor and the place of intensive consolidation should be
considered. Such policies can now be tested in randomised
prospective trials.
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